How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance

In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on: • Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance protocol. • Reducing biopsy usage by 75% and being a “better consumer of biopsies” through dd-cfDNA surveillance. • Aligning his experience with the ProActive Interim Data finding of dd-cfDNA as “a leading indicator that something is wrong”. • His actions when observing increases in dd-cfDNA levels prior to confirming rejection. • Why the American Society of Transplant Surgeon recommends serial dd-cfDNA measurements in kidney transplant recipients.